Lipoprotein-associated phospholipase A2 (Lp-PLA2) is another inflammation biomarker that is unsuitable for use as a therapeutic target while its plasma concentration is linked to the risk prediction of cardiovascular outcomes in patients with stable coronary heart diseases [93]. Here, PLA2G7 is linked to coronary artery disorder.